Joseph D. Buxbaum
Laboratory of Molecular Neuropsychiatry
Department of Psychiatry
Mount Sinai School of Medicine
One Gustave L. Levy Place
USA
Name/email consistency: high
- Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Buxbaum, J.D., Cullen, E.I., Friedhoff, L.T. Front. Biosci. (2002)
- Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. Buxbaum, J.D., Silverman, J.M., Smith, C.J., Kilifarski, M., Reichert, J., Hollander, E., Lawlor, B.A., Fitzgerald, M., Greenberg, D.A., Davis, K.L. Am. J. Hum. Genet. (2001)
- Genomic structure, expression pattern, and chromosomal localization of the human calsenilin gene: no association between an exonic polymorphism and Alzheimer's disease. Buxbaum, J.D., Lilliehook, C., Chan, J.Y., Go, R.C., Bassett, S.S., Tanzi, R.E., Wasco, W., Blacker, D. Neurosci. Lett. (2000)
- Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Buxbaum, J.D., Choi, E.K., Luo, Y., Lilliehook, C., Crowley, A.C., Merriam, D.E., Wasco, W. Nat. Med. (1998)
- Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. Buxbaum, J.D., Liu, K.N., Luo, Y., Slack, J.L., Stocking, K.L., Peschon, J.J., Johnson, R.S., Castner, B.J., Cerretti, D.P., Black, R.A. J. Biol. Chem. (1998)